Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493521 | 0.92 | CD274 (0.35) | CD274TP53MAPK1RAB9ADPP4 | |
| SCHEMBL2491619 | 0.87 | CD274 (0.39) | CD274PDCD1PTGS1ESR2S1PR3 | |
| SCHEMBL2489198 | 0.84 | S1PR3 (0.37) | CD274PDCD1PTGS1ESR2S1PR3 | |
| SCHEMBL2489421 | 0.83 | PDE4B (0.38) | CD274TP53MAPK1RAB9ADPP4 | |
| SCHEMBL2492905 | 0.82 | TP53 (0.40) | CD274TP53MAPK1RAB9ADPP4 | |
| SCHEMBL2491451 | 0.75 | PDE4B (0.37) | CD274TP53MAPK1RAB9ADPP4 | |
| SCHEMBL2489577 | 0.74 | GBA1 (0.35) | TP53MAPK1RAB9ADPP4PTGS1 | |
| SCHEMBL2490820 | 0.73 | TAAR1 (0.39) | CD274TP53MAPK1RAB9ATAAR1 | |
| SCHEMBL9840549 | 0.71 | ELANE (0.41) | CD274RAB9APDCD1PTGS1 | |
| SCHEMBL2491936 | 0.70 | ALDH1A1 (0.38) | ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | CD274 3091/4885TP53 4826/4885MAPK1 172/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | CD274 2885/4885TP53 4797/4885MAPK1 221/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | CD274 2825/4885TP53 4787/4885MAPK1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.